Universal Beteiligungs und Servicegesellschaft mbH Sells 24,727 Shares of Castle Biosciences, Inc. $CSTL

Universal Beteiligungs und Servicegesellschaft mbH lowered its position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) by 45.3% in the 3rd quarter, Holdings Channel.com reports. The fund owned 29,883 shares of the company’s stock after selling 24,727 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Castle Biosciences were worth $680,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Schroder Investment Management Group lifted its position in Castle Biosciences by 8.6% during the 2nd quarter. Schroder Investment Management Group now owns 648,572 shares of the company’s stock valued at $13,198,000 after acquiring an additional 51,483 shares during the period. Advisors Capital Management LLC lifted its holdings in shares of Castle Biosciences by 21.9% during the second quarter. Advisors Capital Management LLC now owns 245,867 shares of the company’s stock valued at $5,021,000 after purchasing an additional 44,180 shares during the last quarter. Campbell & CO Investment Adviser LLC bought a new stake in shares of Castle Biosciences in the 3rd quarter worth approximately $615,000. Squarepoint Ops LLC grew its stake in shares of Castle Biosciences by 29.1% in the 2nd quarter. Squarepoint Ops LLC now owns 125,719 shares of the company’s stock worth $2,567,000 after buying an additional 28,359 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Castle Biosciences by 6.2% in the 2nd quarter. Geode Capital Management LLC now owns 689,926 shares of the company’s stock worth $14,090,000 after buying an additional 40,073 shares during the last quarter. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Guggenheim lifted their price target on Castle Biosciences from $43.00 to $47.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Lake Street Capital upped their target price on shares of Castle Biosciences from $35.00 to $52.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. KeyCorp reissued an “overweight” rating and set a $50.00 price target on shares of Castle Biosciences in a research report on Thursday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Castle Biosciences in a research report on Monday, December 29th. Finally, Zacks Research downgraded Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 2nd. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Castle Biosciences has an average rating of “Moderate Buy” and a consensus target price of $47.14.

Insiders Place Their Bets

In related news, insider Derek J. Maetzold sold 4,017 shares of the stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $40.01, for a total transaction of $160,720.17. Following the completion of the sale, the insider owned 87,715 shares in the company, valued at approximately $3,509,477.15. This trade represents a 4.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Kristen M. Oelschlager sold 14,888 shares of the stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $39.31, for a total transaction of $585,247.28. Following the sale, the chief operating officer directly owned 12,323 shares of the company’s stock, valued at approximately $484,417.13. This trade represents a 54.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 44,781 shares of company stock worth $1,670,060. Corporate insiders own 7.20% of the company’s stock.

Castle Biosciences Price Performance

Shares of Castle Biosciences stock opened at $39.39 on Monday. The stock has a market cap of $1.15 billion, a P/E ratio of -87.53 and a beta of 1.06. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.31 and a current ratio of 6.47. The stock’s fifty day moving average is $39.77 and its 200 day moving average is $29.15. Castle Biosciences, Inc. has a one year low of $14.59 and a one year high of $44.28.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.32. The company had revenue of $80.55 million during the quarter, compared to the consensus estimate of $71.06 million. Castle Biosciences had a positive return on equity of 1.73% and a negative net margin of 3.56%. Sell-side analysts anticipate that Castle Biosciences, Inc. will post 0.44 earnings per share for the current year.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.